Trying to put in perspective the Gilead/IMMU deal at 21Billion..now trading at $80 PPS plus when it ran from June to Sept at about $33 PPS then the stop in trials for efficacy on triple negative breast cancer.
I agree that $70 Billion is a big number for any one Big Pharma to swallow..but, considering the plentiful indications maybe one bite at a time?.......starting with something they don't have in their pipeline. I don't have the expertise in the BioWorld.......throwing darts !